
SAREUM HOLDINGS PLC
Clinical-stage developer of kinase inhibitors for autoimmune disease & cancer.
SAR | IL
Overview
Corporate Details
- ISIN(s):
- GB00BMC3RJ87
- LEI:
- 213800PKERN2DY8FFM72
- Country:
- United Kingdom
- Address:
- UNIT 2A, CB22 3FX CAMBRIDGE
- Website:
- https://www.sareum.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Sareum Holdings PLC is a clinical-stage drug discovery and development company specializing in small molecule therapeutics. The company develops next-generation kinase inhibitors to treat autoimmune diseases and cancer. Its primary focus is on the TYK/JAK kinase cell signalling family, advancing dual inhibitors of TYK2 and JAK1, which it believes offer superior efficacy compared to single-kinase agents. The company's lead autoimmune candidate, SDC-1801, has successfully completed a Phase 1 clinical trial. Sareum's pipeline also includes a Chk1 kinase inhibitor program for oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
Date | Filing | Language | Size | Actions | |
---|---|---|---|---|---|
2025-10-10 08:00 |
Legal Proceedings Report
Update on toxicology study for SDC-1801
|
English | 13.2 KB | ||
2025-10-07 08:00 |
Report Publication Announcement
Notice of Results and Investor Presentation
|
English | 12.2 KB | ||
2025-09-26 16:12 |
Share Issue/Capital Change
Exercise of Warrants
|
English | 10.8 KB | ||
2025-09-18 13:59 |
Share Issue/Capital Change
Exercise of Warrants
|
English | 10.9 KB | ||
2025-08-26 08:00 |
Share Issue/Capital Change
Exercise of Warrants
|
English | 10.5 KB | ||
2025-08-20 11:01 |
Share Issue/Capital Change
Exercise of Warrants
|
English | 10.5 KB | ||
2025-08-12 08:00 |
Regulatory News Service
Sareum Collaboration with Receptor.AI
|
English | 15.3 KB | ||
2025-07-09 08:00 |
Share Issue/Capital Change
Exercise of Warrants
|
English | 10.7 KB | ||
2025-05-29 08:00 |
Regulatory News Service
Initiation of Toxicology Studies for SDC-1801
|
English | 11.4 KB | ||
2025-03-27 08:00 |
Director's Dealing
Director’s Dealing
|
English | 27.8 KB | ||
2025-03-25 08:00 |
Interim Report
Sareum Half-Year Report
|
English | 133.9 KB | ||
2025-03-13 08:15 |
Share Issue/Capital Change
Institutional Equity Fundraise
|
English | 14.4 KB | ||
2025-03-13 08:08 |
Regulatory News Service
Sareum Acquires Licence for SRA737
|
English | 12.8 KB | ||
2024-12-31 08:00 |
Legal Proceedings Report
Update on SRA737
|
English | 13.5 KB | ||
2024-12-19 17:07 |
Post-Annual General Meeting Information
Results of AGM
|
English | 33.8 KB |
Automate Your Workflow. Get a real-time feed of all SAREUM HOLDINGS PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for SAREUM HOLDINGS PLC via our API.
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |